Display options
Cite
Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004;13(1):137-54doi: 10.1023/B:QURE.0000015297.91158.01.
Bacik, J., Mazumdar, M., Murphy, B. A., Fairclough, D. L., Eremenco, S., Mariani, T., Motzer, R. J., & Cella, D. (2004). The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 13(1), 137-54. https://doi.org/10.1023/B:QURE.0000015297.91158.01
Bacik, J, et al. "The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers." Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation vol. 13,1 (2004): 137-54. doi: https://doi.org/10.1023/B:QURE.0000015297.91158.01
Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ, Cella D. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004 Feb;13(1):137-54. doi: 10.1023/B:QURE.0000015297.91158.01. PMID: 15058795.
Copy Download .nbib Format: NLM
Share it on

Qual Life Res. 2004 Feb;13(1):137-54. doi: 10.1023/B:QURE.0000015297.91158.01.

The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

J Bacik, M Mazumdar, B A Murphy, D L Fairclough, S Eremenco, T Mariani, R J Motzer, D Cella

Affiliations

  1. Department of Epidemiology and Biostatistics a Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

PMID: 15058795 DOI: 10.1023/B:QURE.0000015297.91158.01

Abstract

PURPOSE: This paper reports on the development and validation of two biologic response modifier (BRM) subscales for use with the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life (QOL) questionnaire.

METHODS: Using the FACT-G as a base, 17 additional questions related to symptoms common to interferon and retinoid therapy were developed. Data collected at baseline (n = 191) and week 2 (n = 168) in a randomized trial of interferon +/- 13-cis-retinoic acid in advanced renal cell carcinoma patients were used to validate this measure.

RESULTS: Using a combined empirical and conceptual approach, the 17 questions were reduced to 13 questions consisting of two subscales: 'BRM-physical' (7 items; baseline coefficient alpha(alpha) = 0.70; week-2 alpha = 0.75) and 'BRM-mental' (6 items; baseline alpha = 0.79; week-2 alpha = 0.78). Internal consistency of the trial outcome index (TOI) combining physical well-being, functional well-being and the BRM subscales, was 0.91 for baseline assessments and 0.92 for week 2. Discriminant validity was demonstrated for the TOI by its ability to differentiate among prognostic risk groups, and for the total FACT-G, TOI and total FACT-BRM scores by their ability to distinguish between groups differing in performance, response and toxicity status.

CONCLUSIONS: The 'BRM-physical' and 'BRM-mental' subscales can be combined with the FACT-G to form the 'FACT BRM' scale, useful for measuring QOL in cancer patients who are receiving treatment with biologic response modifiers.

References

  1. Cancer Invest. 1998;16(7):478-84 - PubMed
  2. J Pain Symptom Manage. 1997 Feb;13(2):63-74 - PubMed
  3. Stat Med. 1992 Oct-Nov;11(14-15):1861-70 - PubMed
  4. Semin Oncol. 1998 Feb;25(1 Suppl 1):3-8 - PubMed
  5. Qual Life Res. 1996 Jun;5(3):309-20 - PubMed
  6. J Clin Oncol. 2000 Jun;18(11):2316-26 - PubMed
  7. J Clin Oncol. 1993 Mar;11(3):570-9 - PubMed
  8. J Clin Oncol. 1999 Aug;17(8):2530-40 - PubMed
  9. Multivariate Behav Res. 1966 Apr 1;1(2):245-76 - PubMed
  10. Qual Life Res. 1996 Jun;5(3):321-9 - PubMed
  11. J Urol. 1998 Jun;159(6):1988-92 - PubMed
  12. Br J Cancer. 1988 Jan;57(1):109-12 - PubMed
  13. J Urol. 2000 Feb;163(2):408-17 - PubMed
  14. J Clin Oncol. 2000 Aug;18(16):2972-80 - PubMed
  15. Cancer. 1981 Jan 1;47(1):207-14 - PubMed
  16. Semin Oncol. 1998 Feb;25(1 Suppl 1):39-47 - PubMed
  17. Oncologist. 2001;6(1):34-55 - PubMed

Substances

MeSH terms

Publication Types

Grant support